MedTrace Logo

New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer

NCT01365208 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2017-03-24

No results posted yet for this study

Summary

The combination of pEBV DNA (half-life) and PET-CT following 1 course of chemotherapy allow earlier and more detection of drug response in advanced NPC than RECIST method, in patients with previously untreated advanced NPC who will receive platinum-based chemotherapy. This study will also determine if this new method can predict survival in these patients. This study may have far-reaching impact on drug development in NPC as it may offer a more optimal way of evaluating drug efficacy in clinical trials and also in clinical management.

Conditions

  • Advanced Nasopharyngeal Carcinoma

Interventions

DRUG

Chemotherapy

platinum-based chemotherapy

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Brigette Ma, MD, FRCP · Chinese University of Hong Kong

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2017-03-03
Completion
2017-03-03

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01365208 on ClinicalTrials.gov